{"uniprot":"Q96D98","gene":"EID2B","name":"EP300-interacting inhibitor of differentiation 2B","organism":"Homo sapiens (Human)","status":"dark","length":161,"sequence":"MAEPTGLLEMSELPGDSSVPQVGTASGVSDVLRGAVGGGVRVQEAREGPVAEAARSMARMPGPVPGPIPSSVPGLASAPDPHQQLAFLEINRQLLFREYLDGSSMIPVRLLRDFEERRRLFVEGCKAREAAFDADPPQMDFAAVAFTVALTASEALSPLAD","function_summary":"A nuclear transcriptional repressor that assembles through homotypic binding to form inhibitory complexes that antagonize EP300/CBP-mediated coactivation. By dampening chromatin acetylation and transcriptional output, it suppresses gene programs that drive myogenic maturation and broader transcriptional pathways. Its mechanism centers on oligomeric assemblies that sequester or inhibit EP300/CBP at target loci, thereby restraining promoter and enhancer activity in differentiating cells.","plain_language":"EID2B has barely been studied. The model's best guess: A nuclear transcriptional repressor that assembles through homotypic binding to form inhibitory complexes that antagonize EP300/CBP-mediated coactivation. By dampening chromatin acetylation and transcriptional output, it suppresses gene programs that drive myogenic maturation and broader transcriptional pathways.","uniprot_summary":"Inhibits myoblast differentiation.","go_terms":{"molecular_function":[{"id":"GO:0042802","label":"identical protein binding"}],"biological_process":[{"id":"GO:0045662","label":"negative regulation of myoblast differentiation"},{"id":"GO:0045892","label":"negative regulation of DNA-templated transcription"}],"cellular_component":[{"id":"GO:0005634","label":"nucleus"}]},"interpro":[{"id":"IPR033258","name":"EP300-interacting inhibitor of differentiation","type":"family","start":8,"end":161}],"reasoning":"I begin with the InterPro architecture: a single annotated region IPR033258 (EP300-interacting inhibitor of differentiation family) spanning residues 8–161. This family signature defines a conserved core that binds and antagonizes EP300/CBP coactivator function. The compact N-terminal-to-central family domain and the absence of catalytic motifs indicate a non-enzymatic regulator that operates through protein–protein interactions and chromatin-associated assemblies. Such a scaffold-like core typically supports homotypic association, which causally explains GO:0042802 identical protein binding as the molecular function: oligomerization stabilizes higher-order repressor complexes.\n\nFrom this binding-centric architecture, the molecular function propagates to transcriptional control. The EP300/CBP interaction module enables this protein to sequester or inhibit EP300-dependent coactivation, directly reducing histone acetylation and transcriptional output by RNA polymerase II. This mechanism aligns with GO:0045892 negative regulation of DNA-templated transcription. In myogenic lineages, repression of EP300-driven programs curtails expression of myogenic determinants and their downstream effectors, thereby enforcing GO:0045662 negative regulation of myoblast differentiation. The causal chain is: EP300/CBP inhibition lowers chromatin acetylation at target loci, which suppresses transcriptional programs required for terminal myoblast maturation.\n\nCellular localization follows from function and architecture. A regulator that binds EP300/CBP and modulates transcription must operate where chromatin and transcriptional machinery reside—the nucleus. The soluble, non-membranous nature of the family domain and its transcriptional role support GO:0005634 nucleus as the cellular component.\n\nThese features suggest a mechanism: the protein forms homodimers/oligomers via its family core and recruits EP300/CBP into non-productive assemblies, locally reducing histone acetylation and transcriptional initiation/elongation at myogenic gene promoters. It likely interfaces with myogenic transcription factors (e.g., MYOD1, MEF2 family) by competing for EP300/CBP and by tethering to chromatin-bound complexes. Predicted interaction partners therefore include EP300 and CREBBP directly, myogenic TFs that require EP300/CBP coactivation, and chromatin-modifying assemblies that read or write acetylation states. Together, these interactions produce a nuclear repressor hub that restrains myoblast differentiation and broader transcriptional programs.","category":"dark","control_evaluation":null,"validation_plan":null,"structure":{"source":"AlphaFold DB","pdb":"/structures/AF-Q96D98.pdb","alphafold":"https://alphafold.ebi.ac.uk/entry/Q96D98"},"links":{"uniprot":"https://www.uniprot.org/uniprotkb/Q96D98/entry","atlas":"/p/Q96D98"},"provenance":{"model":"BioReason-Pro (ESM3 esm3-sm-open-v1)","source_list":"Pharos Tdark","note":"AI prediction, not experimentally verified"}}